Cargando…

Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery

PURPOSE: To compare the relative effectiveness of a Tri-Moxi-Vanc intraocular solution injected transzonularly into the vitreous with the topical formulation of Pred-Moxi-Ketor (given for the first week postoperatively) followed by Pred-Ketor (given for weeks 2–4 after surgery). PATIENTS AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Bret L, Potvin, Rick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957678/
https://www.ncbi.nlm.nih.gov/pubmed/27486301
http://dx.doi.org/10.2147/OPTH.S112080
_version_ 1782444206061518848
author Fisher, Bret L
Potvin, Rick
author_facet Fisher, Bret L
Potvin, Rick
author_sort Fisher, Bret L
collection PubMed
description PURPOSE: To compare the relative effectiveness of a Tri-Moxi-Vanc intraocular solution injected transzonularly into the vitreous with the topical formulation of Pred-Moxi-Ketor (given for the first week postoperatively) followed by Pred-Ketor (given for weeks 2–4 after surgery). PATIENTS AND METHODS: This was a single-site, single-surgeon, prospective, randomized, subject-masked contralateral eye study with an active comparator and was approved by an appropriate ethics committee. Twenty-five subjects with uncomplicated cataract who were scheduled for cataract surgery were enrolled. If surgery was uneventful, subjects received either an injection in that eye or followed a minimum drop postoperative pharmaceutical regimen. The second eye surgery was performed with the opposite treatment. Subjects were followed for 1 month. Measures of interest were the changes in intraocular pressure (IOP) from baseline and the changes in corneal and macular thickness. Subjects were also asked to evaluate pain perception, visual quality, and overall satisfaction with surgery. They were also asked which regimen they preferred. RESULTS: IOP was not statistically significantly different between the groups (P=0.81); there was also no statistically significant difference in IOP over time (P=0.74). There was no statistically significant difference in central macular thickness at 1 week and 1 month between the groups (P=0.18). The central corneal thickness was significantly greater 1 day postoperatively relative to baseline, but there was no statistically significant difference between the groups at any time point (P=0.92). The difference in reported pain was also not statistically significantly different between the groups (P=0.67). Satisfaction with surgery was similar for both groups, but significantly more subjects preferred the injection for overall experience (P<0.01). CONCLUSION: Cataract surgery completed with the two pharmaceutical regimens was similar in outcome. Significantly more subjects preferred the injection, presumably as a function of the greater convenience with no apparent difference in the therapeutic effect.
format Online
Article
Text
id pubmed-4957678
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49576782016-08-02 Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery Fisher, Bret L Potvin, Rick Clin Ophthalmol Clinical Trial Report PURPOSE: To compare the relative effectiveness of a Tri-Moxi-Vanc intraocular solution injected transzonularly into the vitreous with the topical formulation of Pred-Moxi-Ketor (given for the first week postoperatively) followed by Pred-Ketor (given for weeks 2–4 after surgery). PATIENTS AND METHODS: This was a single-site, single-surgeon, prospective, randomized, subject-masked contralateral eye study with an active comparator and was approved by an appropriate ethics committee. Twenty-five subjects with uncomplicated cataract who were scheduled for cataract surgery were enrolled. If surgery was uneventful, subjects received either an injection in that eye or followed a minimum drop postoperative pharmaceutical regimen. The second eye surgery was performed with the opposite treatment. Subjects were followed for 1 month. Measures of interest were the changes in intraocular pressure (IOP) from baseline and the changes in corneal and macular thickness. Subjects were also asked to evaluate pain perception, visual quality, and overall satisfaction with surgery. They were also asked which regimen they preferred. RESULTS: IOP was not statistically significantly different between the groups (P=0.81); there was also no statistically significant difference in IOP over time (P=0.74). There was no statistically significant difference in central macular thickness at 1 week and 1 month between the groups (P=0.18). The central corneal thickness was significantly greater 1 day postoperatively relative to baseline, but there was no statistically significant difference between the groups at any time point (P=0.92). The difference in reported pain was also not statistically significantly different between the groups (P=0.67). Satisfaction with surgery was similar for both groups, but significantly more subjects preferred the injection for overall experience (P<0.01). CONCLUSION: Cataract surgery completed with the two pharmaceutical regimens was similar in outcome. Significantly more subjects preferred the injection, presumably as a function of the greater convenience with no apparent difference in the therapeutic effect. Dove Medical Press 2016-07-18 /pmc/articles/PMC4957678/ /pubmed/27486301 http://dx.doi.org/10.2147/OPTH.S112080 Text en © 2016 Fisher and Potvin. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Clinical Trial Report
Fisher, Bret L
Potvin, Rick
Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
title Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
title_full Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
title_fullStr Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
title_full_unstemmed Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
title_short Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
title_sort transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957678/
https://www.ncbi.nlm.nih.gov/pubmed/27486301
http://dx.doi.org/10.2147/OPTH.S112080
work_keys_str_mv AT fisherbretl transzonularvitreousinjectionvsasingledropcompoundedtopicalpharmaceuticalregimenaftercataractsurgery
AT potvinrick transzonularvitreousinjectionvsasingledropcompoundedtopicalpharmaceuticalregimenaftercataractsurgery